Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Zenas BioPharma Q2 EPS $(1.25) Misses $(1.04) Estimate

Author: Benzinga Newsdesk | August 12, 2025 06:14am
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(1.04) by 20.19 percent. This is a 94.84 percent increase over losses of $(24.23) per share from the same period last year.

Posted In: ZBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist